Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens

Cancer Clinical Trial

— EPO-CAN  

Official title:

Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01827514
• Other study ID #: TASMC-11-MM-619-CTIL
• Status: Active, not recruiting
• Phase: N/A
• First received: March 13, 2013
• Last updated: April 4, 2013
• Start date: January 2013
• Est. completion date: January 2016

Study information

• Verified date: April 2013
• Source: Tel-Aviv Sourasky Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ethics Commission
• Study type: Observational

Clinical Trial Summary

Erythropoietin, EPO, is the main regulator and stimulator of bone marrow erythropoiesis, and is responsible for growth and differentiation of the erythroid cell lineage. Our team, in collaboration with partners (see below) has taken responsibility to study the presence, function and clinical significance of EPO-R in human cancer specimens.

General Aim of the Proposed Project: To study EPO-R in human cancer specimens. Prepared slides from already taken preparations (specimens from Bone Marrow tests) will serve as the basis for that part of the work.Specimens will be taken from Breast cancer, Colon cancer, Lung cancer, Head & Neck cancer and from Lymph nodes biopsy (positive for lymphoma) The slides will be stained with anti-EPO-R antibodies (Abs).

Description:

Background: Erythropoietin, EPO, is the main regulator and stimulator of bone marrow erythropoiesis, and is responsible for growth and differentiation of the erythroid cell lineage. The cloning of the gene, led to the production of the recombinant product, rHuEPO. rHuEPO has successfully served over the last couple of decades for both research and clinical application. The product has been shown to improve the anemia of end-stage renal disease, cancer-related anemia, as well as other types of anemia and/or blood loss. Improved anemia by rHuEPO is characterized by increased hemoglobin (Hb) and hematocrit (Hct) levels, reduced blood transfusion requirements and an improved quality of life. Thus, the use of rHuEPO has become a routine daily practice in hematology and oncology, with millions of cancer patients with or without anemia treated with rHuEPO. Indeed, rHuEPO has become a blockbuster (over an annual billion dollar sales) and the most common biological product in the market.

In 2003, reports have suggested that breast cancer, and Head and Neck cancer patients, treated with rHuEPO had a shorter survival than patients who had not been treated with the hormone. These reports were followed by several others. However, other reports, including ours, led to different conclusions. Meta-analysis also failed to provide a definitive answer.

Three potential mechanisms, none of them proven so far, have been proposed to explain potential poor prognosis among rHuEPO-treated cancer patients:

1. Stimulation of EPO receptors (EPO-R), existing on the surface of the tumor cells.

2. High level of Hb and Hct, leading to viscosity and thrombotic-like complications.

3. Increased angiogenesis induced by rHuEPO promoting tumor progression. As expected, these conflicting reports elicited a controversy among the clinical hematologic-oncologic communities, reduced the use of the product and led the FDA Oncology Drug Advisory Committee (ODAC) to publish an alert. The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH), as well as the European Organization for Research and Treatment of Cancer (EORTC), published strict guidelines, defining who are the patients and under what circumstances rHuEPO should be or should not be administered.

With our long-time collaborator, Prof. D. Neumann, Sackler Faculty of Medicine, TAU, we have established a European international consortium, with top basic scientists and clinical investigators, with the general aim to study the topic further. Recently, the consortium, led by Prof. Neumann has been notified that the EU has recognised the importance of the project and has decided to fund it with the prestigious FP7 research grant.

Our team, in collaboration with partners (see below) has taken responsibility to study the presence, function and clinical significance of EPO-R in human cancer specimens.

General Aim of the Proposed Project: To study EPO-R in human cancer specimens.

Specific Aims:

To detect EPO-R on tumor cells To test the EPO-R function To follow the patients and study the possible correlation between the presence and function of EPO-R on the tumor specimens and the clinical outcome and prognosis.

Methods:

The Retrospective Project:

(A waiver for informed consent will be requested from January 1990 till December 2011)

• Prepared slides from already taken preparations (specimens) will serve as the basis for that part of the work.

• When required, additional slides from the pathological "block" will be prepared.

• The required specimens:

1. Breast cancer - 50 (from 50 patients)

2. Colon cancer - 50

3. Lung cancer - 50

4. Head & Neck cancer - 50

5. Lymph nodes biopsy (positive for lymphoma) - 50 The samples of cancer tissues from bronchoscopy, endoscopy and FNA/FNB, where there is only a small amount of tissue, will not be used for the study.

• The unstained, non-identified, slides will be transferred to Prof. Drorit Neumann's laboratory, at the Sackler Faculty of medicine, where analysis of the slides for EPO-R content will be performed. Part of these slides will be transferred to Queens University, Belfast, Ireland and the same tests will be performed in the lab of prof. Makswell.

• The slides will be stained with anti-EPO-R antibodies (Abs). These Abs will be generated as a part of the European EPO-CAN project by Dr. John Thompson and his team in Aldevron, Freiburg, Germany.

• In order to prepare formalin-fixed paraffin wax-embedded (FFPE) material, tissue samples are fixed in 10% buffered formalin overnight at room temperature and processed through graded alcohols to paraffin wax. Once embedded, 3-5µm sections are cut onto activated slides and placed in a 37°C incubator overnight. These are ready for immunohistochemistry. This is our standard methodology for single sections. For Tissue Microarrays (TMAs) selected cases are identified and regions of interest marked using haematoxylin and eosin stained slides. The regions are cored from their original blocks and re-embedded according to an established map. Between 50 and 100 cores are sited per block. Serial 3-5µm sections are cut from these and are treated as above. Screening and staining parameter optimisation of the antibodies are performed on single section preparations. Selected antibodies suitable for FFPE material are used to stain TMAs of normal and malignant tissues from a range of tumours, prepared in the Northern Ireland Biobank.

Note: The information collection from the samples will be conducted by anonymous technique and will be separated in irreversible way from the patient's identification details.

The Prospective Project:

(Patient informed consent is required)

• A similar work will be performed but on fresh material samples, that will be taken from biopsies in the operating room.

• Patients will be identified, with a 2-3 year follow-up on the clinical course and an attempt to correlate the course and clinical outcome with the presence and function of the EPO-R on the tumor cells.

Note:

Only a small (tiny) piece of patient tissue will required. Thus, it should not interfere with any other activity or assay required for decision making process for the patient. There will remained enough patient tissue in storage for future medicine tests for therapeutic goals.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 500
• Est. completion date: January 2016
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult (more than 17 years old)

• With one of next cancer types: breast, lung, colon, head, neck and lymphoma

• I prospective part only: that signed ICF

Exclusion Criteria:

• Teenagers below 18 years old

• In prospective part: that did not sign ICF

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

• Cancer

Locations

Country	Name	City	State
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Tel-Aviv Sourasky Medical Center

Country where clinical trial is conducted

Israel, 

References & Publications (5)

Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007 Jan;43(2):258-70. Epub 2006 Dec 19. Review. — View Citation

Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989 Jul 20;321(3):158-63. — View Citation

Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985 Nov;82(22):7580-4. — View Citation

Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan 1;111(1):25-41. Epub 2007 Oct 22. Review. Erratum in: Blood. 2008 Apr 1;111(7):3909. — View Citation

Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood. 1994 Aug 15;84(4):997-1004. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	anti-EPO-R antibodies staining	The specimens from Biopsy/Bone Marrow test will be collected once immediately after ICF signing in prospective part. In retrospective part, the specimens will be taken once from the same donor.	1 year	No
Secondary	Follow up after prospective participants	o Patients will be identified, with a 2-3 year follow-up on the clinical course and an attempt to correlate the course and clinical outcome with the presence and function of the EPO-R on the tumor cells.	3 years	No